ABSTRACT
Polfa Kutno is a producer of medicines and pharmaceuticals, as well as of polfamixes and veterinary drugs. Polfa’s medicines and pharmaceutical products are sold mainly in Russia, Ukraine, Belarus, Holland, India, Switzerland, the republics of the former Yugoslavia, Hungary, Bulgaria, and Denmark. The biggest error made by Polfa was abandoning its sales to large industrial buyers and focusing its efforts on marketing to small private buyers. The new economy has changed considerably the conditions in which Polfa operates. Polfa is a joint-stock company with the state treasury as its sole stockholder. It is controlled by the management board, the supervisory board, and the general assembly of shareholders. Polfa has made extensive investments. In August 1991, machines purchased in Switzerland and in Germany were installed in the department of Gibrescol-Glycosides in a newly erected plant. The investment tasks faced by Polfa call for the external support of a foreign strategic investor.
